Bronco Technology

Bronco Bio (also known as Bronco Technology) is a private, stealth-mode biotechnology company headquartered in Stamford, Connecticut, focused on developing next-generation precision oncology therapeutics. Founded in 2023 by the executive leadership team behind Loxo Oncology, including Josh Bilenker, the company leverages deep expertise in small molecule drug discovery to target specific genetic drivers of cancer. Bronco Bio is backed by top-tier life science investors and aims to build a robust pipeline of targeted therapies that address significant unmet needs in the oncology space. While specific program details remain undisclosed, the company is widely recognized as a high-profile venture in the precision medicine landscape.